Eficacia de la ciclofosfamida endovenosa en el tratamiento de la enfermedad pulmonar intersticial asociada a la esclerosis sistémica;Efficacy of Cyclophospamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis

Archivos de Bronconeumologia

Volumn 47, Issue 5, 2011, Pages 239-245

  Espinosa, Gerard ^a   Simeón, Carmen Pilar ^b   Plasín, Miguel Ángel ^a   Xaubet, Antoni ^a   Muñoz, Xavier ^b   Fonollosa, Vicent ^b   Cervera, Ricard ^a   Vilardell, Miquel ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cyclophosphamide; Interstitial lung disease; Systemic sclerosis; Treatment

Indexed keywords

CARBON MONOXIDE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; SKIN MANIFESTATION; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; FEMALE; MALE; RETROSPECTIVE STUDY; AIRWAY OBSTRUCTION; AMENORRHEA; CLINICAL EVALUATION; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; INFECTION; LEUKOPENIA; LONG TERM CARE; LUNG FUNCTION TEST; LYMPHOCYTOPENIA; SCLERODERMA;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 79955742433     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2011.01.010     Document Type: Article

References (34)

1. Gabrielli A., Avvedimento E.V., Krieg T. Mechanisms of disease: Scleroderma. N Engl J Med. 2009, 360:1989-2003.
2. Wells A.U., Steen V., Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology. 2009, 48:iii40-iii44.
3. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007, 66:940-944.
4. Bouros D., Wells A.U., Nicholson A.G., Colby T.V., Polychronopoulos V., Pantelidis P., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002, 165:1581-1586.
5. Abraham D.J., Krieg T., Distler J., Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology. 2009, 48:iii3-iii7.
6. Ostojic P., Matucci Cerinic M., Silver R., Highland K., Damjanov N. Intersticial lung disease in systemic sclerosis. Lung. 2007, 185:211-220.
7. Miniati I., Valentini G., Matucci Cerinic M. Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario. Arthritis Res Ther. 2009, 11:103.
8. Nadashkevich O., Davis P., Fritzler M., Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006, 25:205-212.
9. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., et al. Cyclophosphamide versus Placebo in Scleroderma Lung Disease. N Eng J Med. 2006, 354:2655-2666. Scleroderma Lung Study Research Group.
10. Hoyles R.K., Ellis R.W., Wellsbury J., Lees B., Newlands P., Goh N.S., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006, 54:3962-3970.
11. Nannini C., West C.P., Erwin P.J., Matteson E.L. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther. 2008, 10:R124.
12. Giacomelli R., Valentini G., Salsano F., Cipriani P., Sambo P., Conforti M.L., et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol. 2002, 29:371-376.
13. Griffiths B., Miles S., Moss H., Robertson R., Veale D., Emery P. Systemic sclerosis and interstitial lung disease: A pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol. 2002, 29:2371-2378.
14. Kowal-Bielecka O., Landewé R., Avouac J., Chwiesko S., Miniati I., Czirjak L., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009, 68:620-628.
15. Wells A.U., Hirani N Thorax. 2008, 63:v1-v58. and on behalf of the BTS Interstitial Lung Disease Guideline Interstitial lung disease guideline Group, a subgroup of the British Thoracic Society Standards of Care Committee, in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.
16. Airò P., Danieli E., Rossi M., Frassi M., Cavazzana I., Scarsi M., et al. Intravenous cyclophosphamide for interstitial lung diases associated to systemic sclerosis: results with an 18-month protocol including a maintenance phase. Clin Exp Rheumatol. 2007, 25:293-296.
17. Silver R.M., Warrick J.H., Kinsella M.B., Staudt L.S., Baumann M.H., Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993, 20:838-844.
18. Masi A.T., Rodnan G.P., Medsger T.A., Altman R., D'Angelo W., Fries J., et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23:581-590.
19. Latsi P.I., Wells A.U. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol. 2003, 15:748-755.
20. Barst R.J., McGoon M., Torbicki A., Sitbon O., Krowka M.J., Olschewski H., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004, 43:S40-S47.
21. Medsger T.A., Bombardieri S., Czirjak L., Scorza R., Della Rosa A., Bencivelli W. Assessment of severity and prognosis in SSc. Clin Exp Rheumatol. 2003, 21:S42-S46.
22. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med. 2000, 161:646-664. American Thoracic Society/European Respiratory Society.
23. Xaubet A., Ancochea J., Blanquer R., Montero C., Morell F., Rodríguez Becerra E., et al. Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas. Arch Bronconeumol. 2003, 39:580-600.
24. Wells A.U., Latsi P., McCune W.J. Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial?. Am J Respir Crit Care Med. 2007, 176:952-953.
25. Tashkin D.P., Elashoff R., Clements P.J., Roth M.D., Furst D.E., Silver R.M., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2years in scleroderma lung disease. Am J Respir Crit Care Med. 2007, 176:1026-1034.
26. Yiannopoulos G., Pastromas V., Antonopoulis I., Katsiberis G., Kalliolias G., Liossis S.N., et al. Combination of intravenous pulses of cyclophosphamide and methyprednisolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int. 2007, 27:357-361.
27. Bérezné A., Ranque B., Valeyre D., Brauner M., Allanore Y., Launay D., et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: A retrospective multicenter open-label study. J Rheumatol. 2008, 35:1064-1072.
28. Gerbino G.J., Goss C.H., Molitor J.A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008, 133:455-460.
29. Koutroumpas A., Ziogas A., Alexiou I., Barouta G., Sakkas L.I. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010, 29:1167-1168.
30. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin N Am. 2003, 29:371-390.
31. Goh N.S.L., Desai S.R., Veeraraghavan S., Hansell D.M., Copley S.M., Maher T.M., et al. Interstitial lung disease in systemic sclerosis. A simple staging system. Am J Respir Crit Care Med. 2008, 177:1248-1254.
32. Pakas I., Ioannidis J.P., Malagari K., Skopouli F.N., Moutsopoulos H.M., Vlachoyiannopoulos P.G. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol. 2002, 29:298-304.
33. Steen V.D., Lanz J.K., Conte C., Owens G.R., Medsger T.A. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum. 1994, 37:1290-1296.
34. Denton C.P., Lapadula G., Mouthon L., Müller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology. 2009, 48:iii32-iii35.